Patents Represented by Attorney, Agent or Law Firm Steven P. Caltrider
  • Patent number: 6630137
    Abstract: The present invention relates to pharmaceutical formulations of activated protein C. The activated protein C formulations of the present invention are more stable than other formulations of activated protein C and demonstrate fewer degradation products over time.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: October 7, 2003
    Assignee: Eli Lilly and Company
    Inventors: Andrew David Carlson, Theodore Arsay Sheliga
  • Patent number: 6489296
    Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: December 3, 2002
    Assignee: Eli Lilly and Company
    Inventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
  • Patent number: 6436397
    Abstract: The present invention is broadly directed to a method for reducing autodegradation of activated protein C during processing and purification. The present invention provides aqueous activated protein C solutions and an improved method of processing of such solutions, comprising conducting such processing at an ionic strength of greater than 150 mM and at a pH of about 5.5 to less than 6.3.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: August 20, 2002
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey Clayton Baker, Andrew David Carlson, Lihua Huang, Theodore Arsay Sheliga
  • Patent number: 6395270
    Abstract: The present invention relates to pharmaceutical formulations of activated protein C which also comprises sucrose, sodium chloride and sodium citrate buffer at a pH between about 5.5 and about 6.5. The activated protein C formulations of the present invention are more stable than other formulations of activated protein C and demonstrate fewer degradation products over time.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventors: Andrew David Carlson, Theodore Arsay Sheliga
  • Patent number: 6268337
    Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: July 31, 2001
    Assignee: Eli Lilly and Company
    Inventors: Brian W. Grinnell, Daniel C Howey, Charles V Jackson
  • Patent number: 6268344
    Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: July 31, 2001
    Assignee: Eli Lilly and Company
    Inventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
  • Patent number: 6232299
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″-(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: May 15, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Patent number: 6117861
    Abstract: This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: ##STR1## and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: September 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: Gary Lowell Engel, Nagy Alphonse Farid, Margaret Mary Faul, Michael Robert Jirousek, Lori Ann Richardson, Leonard Larry Winneroski, Jr.
  • Patent number: 6114320
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: September 5, 2000
    Assignees: Eli Lilly and Company, Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Patent number: 6071514
    Abstract: The present invention provides a method of treatment for patients with a variety of thrombotic disorders including, but not limited to, stroke, venous thrombosis, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, and thrombosis as a result of peripheral vascular surgery. Said treatment is a combination therapy with human aPC and antiplatelet agents including, but not limited to, aspirin (ASA), clopidogrel, ReoPro.RTM. (abciximab), dipyridamole, ticlopidine and IIb/IIIa receptor antagonists. The synergy will result in the ability to reduce the dosages of the agents used in the combination therapy.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: June 6, 2000
    Assignee: Eli Lilly and Company
    Inventors: Brian William Grinnell, Joseph Anthony Jakubowski
  • Patent number: 6057130
    Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: May 2, 2000
    Assignee: Eli Lilly and Company
    Inventor: Brian W. Grinnell
  • Patent number: 6037322
    Abstract: A method of treatment for patients with vascular occlusion and thromboembolic disorders including the acquired disease state of thrombotic stroke, by administering activated protein C. The administration of aPC provides a highly selective therapeutic agent with a low potential for causing bleeding complications. The administration of aPC is beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: March 14, 2000
    Assignee: Eli Lilly and Company
    Inventors: Brian W. Grinnell, Daniel C Howey, Charles V Jackson
  • Patent number: 5952297
    Abstract: The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5% of the analog present in the suspension is in the dissolved state.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: September 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael R. De Felippis, Bruce H. Frank
  • Patent number: 5939387
    Abstract: The present invention is in the field of human medicine, particularly in the treatment of Non-insulin Dependent Diabetes Mellitus (NIDDM) and other insulin resistant states such as those associated with obesity and aging. The invention provides a method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Carol Lynn Broderick, Richard Dennis DiMarchi, Mark Louis Heiman, Lawrence Edward Stramm
  • Patent number: 5851995
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: December 22, 1998
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Richard D. DiMarchi, David B. Flora, William F. Heath, Jr., James A. Hoffmann, Brigitte E. Schoner, James E. Shields, David L. Smiley
  • Patent number: 5840517
    Abstract: The present invention is directed to an improved process for preparing in high yield an obesity protein analog using a dipeptidylaminopeptidase isolated from the slime mold, Dictyostelium discoideum.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: November 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Paul Robert Atkinson, Lisa Kay Foster, Thomas Charles Furman, Warren Cameron MacKellar
  • Patent number: 5831017
    Abstract: The present invention provides novel compounds, which comprise an obesity protein analog complexed with a divalent metal cation, pharmaceutical formulations thereof, and methods of using such compounds for treating obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: November 3, 1998
    Assignee: Eli Lilly and Company
    Inventor: James Arthur Hoffmann
  • Patent number: RE37720
    Abstract: The present invention is a method of using the BK enhancer in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene product for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventor: Brian W. Grinnell
  • Patent number: RE37806
    Abstract: The present invention is a method of using the BK enhances in tandem with a eukaryotic promoter to promote transcription of DNA that encodes a useful substance. The method of the present invention requires the presence of the E1A gene produce for maximum expression of the useful substance. The present invention also comprises a number of useful expression vectors that comprise the BK enhancer in tandem with the adenovirus 2 late promoter positioned to drive expression of a variety of proteins, such as protein C, chloramphenicol acetyltransferase, and tissue plasminogen activator. The present invention further comprises a method for increasing the activity of the BK enhancer involving placement of the BK enhancer immediately upstream of the eukaryotic promoter used in tandem with the BK enhancer to drive expression of a useful substance. Furthermore, the present invention also comprises a method for coamplification of genes in primate cells.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: July 23, 2002
    Assignee: Eli Lilly and Company
    Inventor: Brian W. Grinnell
  • Patent number: RE37971
    Abstract: The present invention relates to the acylation of proteins. More particularly, the invention relates to a one-step process for selectively acylating the free &egr;-amino group of insulin, insulin analog, or proinsulin in the presence of a free &agr;-amino group.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: January 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey C. Baker, Victor J. Chen, Jose M. Hanquier, Aidas Kriauciunas, Brian A. Moser, Robert T. Shuman